Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Movement disorders in pregnancy.

Marsha S A Smith1, Marian L Evatt

  • 1Emory University School of Medicine, Atlanta, GA, USA.

Neurologic Clinics
|October 12, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial.

JAMA neurology·2025
Same author

Rationale and Design of the PAIRED Trial: Partnered Dance Aerobic Exercise as a Neuroprotective, Motor, and Cognitive Intervention in Parkinson's Disease.

Frontiers in neurology·2020
Same author

DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.

Neurology. Genetics·2016
Same author

Vitamin D associations and sleep physiology-promising rays of information.

Sleep·2015
Same author

Vitamin D from different sources is inversely associated with Parkinson disease.

Movement disorders : official journal of the Movement Disorder Society·2014
Same author

Parkinson disease: Low vitamin D and Parkinson disease--a causal conundrum.

Nature reviews. Neurology·2013

Movement disorders in pregnancy are rare, with restless legs syndrome (RLS) and chorea gravidarum (CG) being exceptions. Treatment decisions for pregnant patients with movement disorders require careful consideration of drug safety, especially dopaminergic agents.

Area of Science:

  • Neurology
  • Obstetrics
  • Pharmacology

Background:

  • Movement disorders during pregnancy are uncommon, with restless legs syndrome (RLS) and chorea gravidarum (CG) being notable exceptions.
  • The incidence of rheumatic fever has decreased, necessitating broader differential diagnoses for CG, including systemic lupus erythematosus and antiphospholipid antibody syndrome.

Purpose of the Study:

  • To review the management of movement disorders during pregnancy.
  • To provide guidance on the safe use of pharmacological agents for neurological conditions in pregnant patients.

Main Methods:

  • Literature review of movement disorders in pregnancy.
  • Analysis of drug safety data, including animal studies and case reports, for dopaminergic agents, amantadine, selegiline, and neuroleptics.

Related Experiment Videos

Main Results:

  • Pergolide (dopamine agonist) can be continued for Parkinson's disease (PD), Segawa disease, and RLS. Levodopa and ropinirole use should be limited due to potential teratogenicity.
  • Amantadine is contraindicated in pregnancy. Selegiline data are controversial. High-potency neuroleptics like haloperidol are preferred for Tourette syndrome symptoms.
  • Depression is a common comorbidity; its treatment in pregnancy is discussed separately. Most drug data in pregnancy are limited, requiring clinical judgment.

Conclusions:

  • Neurologists must weigh individual patient factors, clinical judgment, and limited safety data when prescribing medications for movement disorders during pregnancy.
  • Careful consideration of potential risks and benefits is crucial for managing dopaminergic agents, amantadine, selegiline, and neuroleptics in pregnant individuals.